# Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

> **NCT03436732** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 5 (actual)

## Conditions studied

- Mesothelioma

## Interventions

- **DRUG:** LMB-100
- **DRUG:** SEL-110

## Key facts

- **NCT ID:** NCT03436732
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-28
- **Primary completion:** 2019-04-30
- **Final completion:** 2019-04-30
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Due to fatal occurrence (pneumonitis) attributed to one of the study drugs.
- **Last updated:** 2019-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03436732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03436732, "Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03436732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*